Skip to main content

Advertisement

SpringerLink
Log in

Interferon γ but not tumor necrosis factor α decreases susceptibility of human renal cell cancer cell lines to lymphokine-activated killer cells

  • Original articles
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Summary

Human renal cell cancer (RCC) cell lines, ACHN and KRC/Y, with or without exposure to cytokines, were examined for their susceptibility to lymphokine-activated killer (LAK) cells. Flow-cytometric analysis demonstrated constitutional expression of class I antigen on both cell lines, which was enhanced by interferon α (IFNα), IFNγ and tumor necrosis factor α (TNFα). A 4-h51Cr-release cytotoxicity assay demonstrated that pretreatment of both cell lines with IFNγ or IFNα, but not with TNFα, decreased their susceptibility to LAK cells. IFNγ also decreased susceptibility to natural killer cells in a 16-h51Cr-release cytotoxicity assay. IFNγ treatment decreased the susceptibility of ACHN cells in a dose-dependent manner. “Cold”-target competition assay clearly showed that IFNγ- but not TNFα-pretreated cells compete less effectively than do untreated target cells. Pretreatment with IFNγ, however, increased expression of intercellular adhesion molecule-1 (ICAM-1) to a degree comparable to that with TNFα. Northern blot analyses using a 520-base-pair ICAM-1 cDNA as a probe demonstrated that more 3.3-kb mRNA is expressed in IFNγ- and TNFα-pretreated cells. These results suggest that IFNγ-treated RCC cell lines may reduce their ability to be recognized by LAK cells, and that IFN-induced protection of RCC cell lines against LAK cells may depend upon a mechanism independent of the expression of class I antigens or ICAM-1 on tumor cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Blick M, Sherwin SA, Rosenblum M, Gutterman J (1987) Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res 47: 2986

    PubMed  Google Scholar 

  2. Braakman E, Goedegbuure PS, Vreugdenhil RJ, Segal DM, Shaw S, Bolhuis RLH (1990) ICAM-1− melanoma cells are relatively resistant to CD3-mediated T-cell lysis. Int J Cancer 46: 475

    PubMed  Google Scholar 

  3. Brocker EB, Zwadlo G, Holzmann B, Macher E, Sorg C (1988) Inflammatory cell infiltrates in human melanoma at different stages of tumor progression. Int J Cancer 41: 562

    PubMed  Google Scholar 

  4. Brunda MJ, Bellantoni D, Sulich V (1987) In vivo antitumor activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells. Int J Cancer 40: 365

    PubMed  Google Scholar 

  5. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ (1979) Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18: 5294

    PubMed  Google Scholar 

  6. De Fries RU, Golub SH (1988) Characteristics and mechanism of IFN-γ-induced protection of human tumor cells from lysis by lymphokine-activated killer cells. J Immunol 140: 3686

    PubMed  Google Scholar 

  7. Freed SZ, Halperin JP, Gordon M (1977) Idiopathic regression of metastasis from renal cell carcinoma. J Urol 118: 538

    PubMed  Google Scholar 

  8. Goedegebuure PS, Braakman E, Segal DM, Vreugdenhil RJ, Bolhuis RLH (1990) Lymphocyte function-associated antigen 1 interacting with target cell intercellular adhesion molecule 1 co-activates cytolysis triggered via CD16 or the receptor involved in major histocompatibility antigen-unrestricted lysis. Int J Immunol 2: 1213

    Google Scholar 

  9. Goldstein D, Laszlo J (1986) Interferon therapy in cancer: from imaginon to interferon. Cancer Res 46: 4315

    PubMed  Google Scholar 

  10. Gronberg A, Ferm MT, Reynolds CW, Ortaldo JR (1988) IFN-γ treatment of K562 cells inhibits natural killer cell triggering and decreases the susceptibility to lysis by cytoplasmic granules from large granular lymphocytes. J Immunol 140: 4397

    PubMed  Google Scholar 

  11. Hamada H, Petrino MG, Kakunaga T (1982) A novel repeated element with Z-DNA-forming potential is widely found in evolutionarily diverse eukaryotic genomes. Proc Natl Acad Sci USA 79: 6465

    PubMed  Google Scholar 

  12. Hinuma S, Onda H, Naruo K Ichimori Y, Koyama M, Tsykamoto K (1982) Translation of interleukin 2 mRNA from human peripheral blood leukocytes inXenopus oocytes. Biochem Biophys Res Commun 109: 363

    PubMed  Google Scholar 

  13. Karre K, Ljunggren HG, Piontek G, Kiessling R (1986) Selective rejection of H-2 deficient lymphoma variants suggests alternative immune defence strategy. Nature 319: 675

    PubMed  Google Scholar 

  14. Krown SE (1987) Interferon treatment of renal cell carcinoma: current status and future prospects. Cancer 59: 647

    PubMed  Google Scholar 

  15. Leiden JM, Karpinski BA, Gottschalk L, Kornbluth J (1989). Susceptibility to natural killer cell-mediated cytolysis is independent of the level of target cell class I HLA expression. J Immunol 142: 2140

    PubMed  Google Scholar 

  16. Makgoba MW, Sanders ME, Ginther Luce GE, Dustin ML, Springer TA, Clark EA, Mannoni P, Shaw S (1988) ICAM-1 a ligand for LFA-1-dependent adhesion of B, T, and myeloid cells. Nature 331: 86

    PubMed  Google Scholar 

  17. Makgoba MW, Sanders ME, Ginther Luce GE, Gugel EA, Dustin ML, Springer TA, Shaw S (1988) Functional evidence that intercellular adhesion molecule-1 (ICAM-1) is a ligand for LFA-1-dependent adhesion in T cell-mediated cytotoxicity, Eur J Immunol 18: 637

    PubMed  Google Scholar 

  18. Mandeville R, Lamoureux G, Legault-Poisson S, Poisson R (1982) Biological markers and breast cancer. A multiparametric study: II. Depressed immune competence. Cancer 50: 1280

    PubMed  Google Scholar 

  19. Miyatake S, Kikuchi H, Oda Y, Nishioka T, Takahashi J, Kondoh S, Matsumoto M, Yamasaki T, Iwasaki K, Aoki T, Kasakura S, Namba Y (1990) Decreased susceptibility of lined human human gliosarcoma cells to lymphokine-activated killer cell cytolysis by γ-interferon treatment. Cancer Res 50: 596

    PubMed  Google Scholar 

  20. Nakano T, Imai K (1991) Expression of ICAM-1 molecule on the surface of hematopoietic tumor cells and detection of ICAM-1 antigen in patients' serum. Sapporo Med J 60:

  21. Ramani P, Blakwill FR (1987) Enhanced metastasis of a mouse carcinoma after in vitro treatment with murine interferon gamma. Int J Cancer 40: 830

    PubMed  Google Scholar 

  22. Rosenberg SA (1988) Immunotherapy of cancer using interleukin-2: current status and future prospects. Immunol Today 9: 58

    PubMed  Google Scholar 

  23. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 316: 889

    PubMed  Google Scholar 

  24. Schmid SM, Borden EC, Bryan GT, Trump DL, Cummings KB (1984) Antiproliferative effects of recombinant interferons alpha, beta, and gamma on renal carcinoma cells. Surg Forum 35: 655

    Google Scholar 

  25. Silagi S, Dutkoeski R, Schaefer A (1988) Eradication of mouse melanoma by combined treatment with recombinant human interleukin 2 and recombinant murine interferon-gamma. Int J Cancer 41: 315

    PubMed  Google Scholar 

  26. Springer TA, Dustin ML, Kishimoto TK, Marlin SD (1987) The lymphocyte function-associated LFA-1, CD2, and LFA-3 molecules: cell adhesion receptors of immune system. Annu Rev Immunol 5: 223

    PubMed  Google Scholar 

  27. Tayloer-Papadimitriou J (1980) Effects of IFN on cell growth and function. Interferon 2: 13

    Google Scholar 

  28. Tokino T, Takahashi E, Mori M, Tanigami A, Glaser T, Park W, Jones C, Hori T, Nakamura Y (1991) Isolation and mapping of 62 new RFLP makers on human chromosome 11. Am J Hum Genet 48: 258

    PubMed  Google Scholar 

  29. Tomita Y, Nishiyama T, Watanabe H, Fujiwara M, Sato S (1990) Expression of intercellular adhesion molecule-1 (ICAM-1) on renal cell cancer: possible significance in host immune responses. Int J Cancer 46: 1001

    PubMed  Google Scholar 

  30. Tomita Y, Nishiyama T, Fujiwara M, Sato S (1990) Immunohistochemical detection of major histocompatibility complex class I and II antigens and quantitiative analysis of tumor infiltrating mononuclear cells in renal cell cancer. Br J Cancer 62: 354

    PubMed  Google Scholar 

  31. Trinchieri G, Granato D, Perussia B (1981) Interferon-induced resistance of fibroblasts to cytolysis mediated by natural killer cells: specificity and mechanism. J Immunol 126: 335

    PubMed  Google Scholar 

  32. Tsai L, Ohlen C, Ljunggren H-G, Karre K, Hansson M, Kiessling R (1989) Effect of IFN-γ treatment and in vivo passage of murine tumor cell lines on their sensitivity to lymphokineactivated killer (LAK) cell lysis in vitro; association with H-2 expression on the target cells. Int J Cancer 44: 669

    PubMed  Google Scholar 

  33. Vadhan-Raj S, Al-Katib A, Bhalla R, Pelus L, Nathan CF, Sherwin SA, Oettgen HF, Krown SE (1986) Phase I trial of recombinant interferon gamma in cancer patients. J Clin Oncol 4: 137

    PubMed  Google Scholar 

  34. Watanabe H, Saitoh T, Fujiwara M (1989) Responsiveness of T cells to mutant major histocompatibility complex class I antigen: II. Role of stimulator-type accessory cells with reference to interleukin 1 production. Scand J Immunol 29: 343

    PubMed  Google Scholar 

  35. Yano H, Maruiwa M, Sugihara S, Kojiro M, Noda S, Eto K (1987) Establishment and characterization of a new human renal cell carcinoma cell line (KRC/Y). In vitro Cell Dev Biol 24: 9

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Niigata University School of Medicine, Japan

    Yoshihiko Tomita, Tsutomu Nishiyama & Shotaro Sato

  2. Department of Immunology, Niigata University School of Medicine, Asahimachi-1, 951, Niigata, Japan

    Hisami Watanabe & Michio Fujiwara

  3. Department of Neurology, Brain Research Institute, Niigata University Niigata, Japan

    Hisashi Kobayashi & Shoji Tsuji

Authors
  1. Yoshihiko Tomita
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hisami Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hisashi Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tsutomu Nishiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shoji Tsuji
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Michio Fujiwara
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shotaro Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tomita, Y., Watanabe, H., Kobayashi, H. et al. Interferon γ but not tumor necrosis factor α decreases susceptibility of human renal cell cancer cell lines to lymphokine-activated killer cells. Cancer Immunol Immunother 35, 381–387 (1992). https://doi.org/10.1007/BF01789016

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01789016

Key words

Search

Navigation